Absorption of magnesium through a transdermal cream Skin and Connective Tissue Diseases
Conditions
Interventions
The participants were randomly assigned to one of the following two treatments:
1. The magnesium cream (intervention)
2. An aqueous cream (placebo)
Thi
Sponsors
University of Hertfordshire
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males and females 2. Aged 18-60 years 3. In good health 4. Not taking any medication (with the exception of the contraceptive pill and asthma inhalers) 5. Not taking a magnesium supplement in any form 6. Not having a blood-borne disease
Exclusion criteria
Exclusion criteria: 1. Younger than 18 years and older than 60 years 2. Not in good health 3. Taking medication (with the exception of the contraceptive pill and asthma inhalers) 4. Taking a magnesium supplement 5. Having a blood-borne disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Serum magnesium levels, measured through venepuncture blood collection at baseline and again within the last 2 days of the intervention. 2. Urinary excretion, measured using 24h collection and analysed at baseline and again within the last 2 days of the intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Habitual dietary magnesium intake, assessed via 2 x 4 day food diaries, of which 4 days were collected at the beginning of the trial and a further 4 days at the end of the trial 2. General feeling of well being, assessed using a EQ-5D Health survey and short questionnaire before and after the intervention | — |
Countries
England, United Kingdom
Outcome results
None listed